MX427593B - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. - Google Patents

Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.

Info

Publication number
MX427593B
MX427593B MX2019005627A MX2019005627A MX427593B MX 427593 B MX427593 B MX 427593B MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 427593 B MX427593 B MX 427593B
Authority
MX
Mexico
Prior art keywords
atherosclerosis
pcsk9
ldl
cardiovascular disease
combination therapies
Prior art date
Application number
MX2019005627A
Other languages
English (en)
Other versions
MX2019005627A (es
Inventor
Narimon Honarpour
Ransi Mudalinayake Somaratne
Robert Andrew Donald Scott
Scott Wasserman
Stephen Nicholls
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX427593(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019005627A publication Critical patent/MX2019005627A/es
Publication of MX427593B publication Critical patent/MX427593B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proporcionan combinaciones de terapias que posibilitan el tratamiento, incluyendo la regresion, de la ateroesclerosis y/o la mejora de los resultados cardiovasculares. Descrito de modo general, esto incluye un primer agente reductor del LDL-C distinto de PCSK9 (tal como una estatina u otra terapia reductora de LDL-C distinta de PCSK9), combinado con una segunda terapia con inhibidor de PCSK9 (tal como un anticuerpo contra PCSK9 o anti-ARN). Se ha determinado que la aplicacion de ambas terapias, a niveles adecuadamente elevadas a fin de reducir el nivel de LDL-C del sujeto hasta niveles muy bajos, durante un periodo de tiempo adecuado, proporciona un beneficio anadido de proteccion adicional frente a la ateroesclerosis y mejora los resultados cardiovasculares de un sujeto.
MX2019005627A 2016-11-14 2017-11-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. MX427593B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10
PCT/US2017/061346 WO2018089912A2 (en) 2016-11-14 2017-11-13 Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease

Publications (2)

Publication Number Publication Date
MX2019005627A MX2019005627A (es) 2019-10-14
MX427593B true MX427593B (es) 2025-10-13

Family

ID=60484496

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019005627A MX427593B (es) 2016-11-14 2017-11-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.
MX2025002106A MX2025002106A (es) 2016-11-14 2019-05-14 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica
MX2024000805A MX2024000805A (es) 2016-11-14 2019-05-14 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2025002106A MX2025002106A (es) 2016-11-14 2019-05-14 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica
MX2024000805A MX2024000805A (es) 2016-11-14 2019-05-14 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.

Country Status (17)

Country Link
US (1) US20200368350A1 (es)
EP (1) EP3538149A2 (es)
JP (3) JP2019533715A (es)
KR (2) KR20240096648A (es)
CN (1) CN110234350A (es)
AU (2) AU2017356219A1 (es)
BR (1) BR112019009726A2 (es)
CA (1) CA3043700A1 (es)
CL (2) CL2019001304A1 (es)
CO (1) CO2019004814A2 (es)
IL (2) IL326501A (es)
JO (1) JOP20190112A1 (es)
MA (1) MA46758A (es)
MX (3) MX427593B (es)
TN (1) TN2019000156A1 (es)
WO (1) WO2018089912A2 (es)
ZA (1) ZA201902975B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
WO2020028124A1 (en) * 2018-07-31 2020-02-06 Wen Tan NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
CN114127770A (zh) 2019-07-19 2022-03-01 电子湾有限公司 样本增量监视
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
HUE047951T2 (hu) * 2015-01-09 2020-05-28 Global Genomics Group Llc Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására

Also Published As

Publication number Publication date
BR112019009726A2 (pt) 2019-08-13
WO2018089912A3 (en) 2018-06-21
TN2019000156A1 (en) 2020-10-05
JOP20190112A1 (ar) 2019-05-14
AU2017356219A1 (en) 2019-05-30
IL266579A (en) 2019-07-31
MX2025002106A (es) 2025-04-02
CL2019001304A1 (es) 2019-09-23
CL2020002993A1 (es) 2021-05-14
US20200368350A1 (en) 2020-11-26
AU2024278180A1 (en) 2025-01-09
IL326501A (en) 2026-04-01
ZA201902975B (en) 2020-01-29
KR20190085963A (ko) 2019-07-19
WO2018089912A2 (en) 2018-05-17
CN110234350A (zh) 2019-09-13
MX2024000805A (es) 2024-02-06
EP3538149A2 (en) 2019-09-18
KR20240096648A (ko) 2024-06-26
CO2019004814A2 (es) 2019-07-31
JP2019533715A (ja) 2019-11-21
JP2023071715A (ja) 2023-05-23
JP2025102770A (ja) 2025-07-08
MX2019005627A (es) 2019-10-14
CA3043700A1 (en) 2018-05-17
MA46758A (fr) 2019-09-18